

Reply to Official Action

Application Serial No. 08/921,060

Page 2

weight results in nearly complete peripheral B cell depletion within about 24 hours post treatment infusion; and

- (ii) administration of at least one chemotherapeutic agent.

17. The method of Claim 16, wherein said chimeric anti-CD20 antibody is administered once a week at said dosage for about 2 to 10 weeks.

18. The method of Claim 17, wherein said chimeric antibody is administered four weeks.

19. The method of Claim 11, wherein said chimeric anti-CD20 antibody is produced by a transfecoma which has been deposited in TCAE8, ATCC deposit number 69119.

20. The method of Claim 19, wherein the at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, vincristine and prednisone.--

See the attached Appendix for the changes made to effect the above claim(s).